Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06517940 · ClinicalTrials.gov registry record
A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)
A clinical trial of Retinitis Pigmentosa, sponsored by Sumitomo Pharma America.
- Active
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT06517940: Active study of Retinitis Pigmentosa, sponsored by Sumitomo Pharma America.
NCT06517940 is a study of Retinitis Pigmentosa that is active but no longer recruiting, run by Sumitomo Pharma America. The registered enrollment target is 12 participants, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06517940, a study of Retinitis Pigmentosa, is active but no longer recruiting, sponsored by Sumitomo Pharma America.
- ACTIVE NOT RECRUITING
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The natural history in individuals with severe retinitis pigmentosa (RP) is variable and there remains an unmet need to better understand disease progression in this population. The goal of this study is to determine which visual assessments individuals with RP and low visual acuity can reliably perform and to evaluate the annual decline of visual function in severe RP.
Primary Outcome
Reliability (test-retest variability within subjects) on: * Total visual area (degrees squared) on kinetic perimetry using III-4e stimulus (excluding temporal islands) (Time frame: 12 months) * Early Treatment of Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) Log of Minimum Angle of Resolution (LogMAR) equivalent (or Low Vision Test, as applicable) (Time frame: 12 months) * Retinal light sensitivity on Full-field Stimulus Threshold test (Time frame: 12 months) * Retinal
Conditions Studied
Study Locations (1)
Massachusetts
- Mass Eye and Ear - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-10-03 |
| Est. Completion | 2026-04-24 |
What the registry record for NCT06517940 still lists
NCT06517940 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 0 interventions.
NCT06517940 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06517940 about?
NCT06517940 is a clinical study titled "A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)". The natural history in individuals with severe retinitis pigmentosa (RP) is variable and there remains an unmet need to better understand disease progression in this population. The goal of this study is to determine which visual assessments individuals with RP and low visual acuity can reliably per...
What is the current status of trial NCT06517940?
This trial is currently active not recruiting. The enrollment target is 12 participants. The study started on 2024-10-03. Estimated completion is 2026-04-24.
What conditions does trial NCT06517940 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa.
Who is sponsoring clinical trial NCT06517940?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06517940 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06517940's enrollment target sits among peer trials
12 32nd of 37 higher than 5 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Retinal Imaging in Patients With Inherited Retinal Degenerations
RECRUITING
-
Cell Collection to Study Eye Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI